Abstract
Despite the variety of available female contraceptive methods, many pregnancies (∼50%) are still undesired. Many men (>60%) want to participate equally with their partner in family planning; however, male contraceptive methods (MCMs) account for only 14% of those used worldwide and no pharmaceutical MCM is available so far. The only two MCMs currently available are condoms, which despite protecting against sexually transmitted diseases have high failure rates (∼19%), and vasectomy, which though very efficient (99%) is poorly reversible (<50%). Among MCMs under investigation, male hormonal contraceptives (MHCs) are those that have come closest to commercialization. The action of MHCs relies on the disruption of spermatogenesis that exogenous androgen administration evokes by suppressing the hypophyseal-gonadal axis. Various regimens of androgens as monotherapy or in combination with progestins have been tested in clinical trials achieving a Pearl Index <1.0 (equal to that of the female oral contraceptive pill); however, concerns regarding the variable response rates observed (non-responders: 5–20%), the impracticality of parenteral administration and long-term prostate-associated or cardiovascular morbidity have deflected the interest of the pharmaceutical industry from further research. Non-hormonal contraception methods may be, at least theoretically, more specific by selectively disrupting spermatogenesis and sperm transport or fertilizing ability. Nevertheless, only a few have been tested in clinical trials (Reversible Inhibition of Sperm Under Guidance, RISUG, and Intra Vas Plugs); most of them are still in pre-clinical development or have been abandoned due to toxicity (gossypol). Consequently, until a reliable, safe and practical MCM is developed, women will continue to bear most of the contraception burden.
Article PDF
Similar content being viewed by others
References
Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat 2007 World population prospects: the 2006 revision and world urbanization prospects: the 2005 revision.
Finer LB, Henshaw SK, 2003 Abortion incidence and services in the United States in 2000. Perspect Sex Reprod Health 35: 6–15.
Trussell J, 1998 Emergency contraception: WHO Task Force study. Lancet 352: 1222–1223.
Anderson RA, Van Der Spuy ZM, Dada OA, et al, 2002 Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone. Hum Reprod 17: 2869–2877.
Lewin A, Mitchell SJ, Hodgkinson S, Gilmore J, Beers LS, 2014 Pregnancy intentions among expectant adolescent couples. J Pediatr Adolesc Gynecol 27: 172–176.
Heinemann K, Saad F, Wiesemes M, Heinemann LA, 2005 Expectations toward a novel male fertility control method and potential user types: results of a multinational survey. J Androl 26: 155–162.
Glasier AF, Anakwe R, Everington D, et al, 2000 Would women trust their partners to use a male pill? Hum Reprod 15: 646–649.
Mommers E, Kersemaekers WM, Elliesen J, et al, 2008 Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 93: 2572–2580.
Page ST, Amory JK, Bremner WJ, 2008 Advances in male contraception. Endocr Rev 29: 465–493.
Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ, 2004 Use of contraception and use of family planning services in the United States: 1982–2002. Adv Data 1–36.
April K, Köster R, Schreiner W, 1993 [How effectively do condoms prevent HIV transmission?]. Med Klin (Munich) 88: 304–311.
Steiner M, Foldesy R, Cole D, Carter E, 1992 Study to determine the correlation between condom breakage in human use and laboratory test results. Contraception 46: 279–288.
Dowbiggin I 2008 The Sterilization Movement and Global Fertility in the Twentieth Century. Oxford University Press New York
Schwingl PJ, Guess HA, 2000 Safety and effectiveness of vasectomy. Fertil Steril 73: 923–936.
Rizvi SA, Naqvi SA, Hussain Z, 1995 Ethical issues in male sterilization in developing countries. Br J Urol 76: Suppl 2: 103–105.
Trussell J, Hatcher RA, Cates W, Stewart FH, Kost K, 1990 Contraceptive failure in the United States: an update. Stud Fam Plann 21: 51–54.
Goldstein M, 1983 Vasectomy failure using an open-ended technique. Fertil Steril 40: 699–700.
Siddiqui MM, Wilson KM, Epstein MM, et al, 2014 Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol 32: 3033–3038.
Cos LR, Valvo JR, Davis RS, Cockett AT, 1983 Vasovasostomy: current state of the art. Urology 22: 567–575.
Goldstein M, Li PS, Matthews GJ, 1998 Microsurgical vasovasostomy: the microdot technique of precision suture placement. J Urol 159: 188–190.
Engelmann UH, Schramek P, Tomamichel G, Deindl F, Senge T, 1990 Vasectomy reversal in central Europe: results of questionnaire of urologists in Austria, Germany and Switzerland. J Urol 143: 64–67.
Heidenreich A, Bonfig R, Wilbert DM, Strohmaier WL, Engelmann UH, 1994 Risk factors for antisperm antibodies in infertile men. Am J Reprod Immunol 31: 69–76.
Belker AM, Thomas AJ, Fuchs EF, Konnak JW, Sharlip ID, 1991 Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. J Urol 145: 505–511.
Roth MY, 2012 Male hormonal contraception. Virtual Mentor 14: 126–132.
Aaltonen P, Amory JK, Anderson RA, et al, 2007 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. J Androl 28: 362–363.
World Health Organization Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336: 955–959.
World Health Organization Task Force on Methods for the Regulation of Male Fertility 1996 Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65: 821–829.
Gu YQ, Wang XH, Xu D, et al, 2003 A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88: 562–568.
McLachlan RI, Robertson DM, Pruysers E, et al, 2004 Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab 89: 142–149.
Gu Y, Liang X, Wu W, et al, 2009 Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 94: 1910–1915.
Kamischke A, Plöger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E, 2000 Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol (Oxf) 53: 43–52.
Waites GM, 2003 Development of methods of male contraception: impact of the World Health Organization Task Force. Fertil Steril 80: 1–15.
Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E, 1995 Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80: 2394–2403.
Handelsman DJ, Conway AJ, Boylan LM, 1992 Suppression of human spermatogenesis by testosterone implants. J Clin Endocrinol Metab 75: 1326–1332.
McLachlan RI, 2000 Male hormonal contraception: a safe, acceptable and reversible choice. Med J Aust 172: 254–255.
Nieschlag E, Hoogen H, Bölk M, Schuster H, Wickings EJ, 1978 Clinical trial with testosterone undecanoate for male fertility control. Contraception 18: 607–614.
Amory JK, Bremner WJ, 2005 Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab 90: 2610–2617.
Gonzalo IT, Swerdloff RS, Nelson AL, et al, 2002 Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 87: 3562–3572.
Vigen R, O’Donnell CI, Barón AE, et al, 2013 Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310: 1829–1836.
Bhasin S, Woodhouse L, Storer TW, 2001 Proof of the effect of testosterone on skeletal muscle. J Endocrinol 170: 27–38.
Nieschlag E. 2010 Male contribution to contraception. In: Andrology, 3rd Edition edn. Springer-Verlag, Berlin Heidelberg; pp. 557–564
Raynaud JP, 2006 Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 102: 261–266.
Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F, 2005 Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 96: 95–108.
Sjögren B, Gottlieb C, 2001 Testosterone for male contraception during one year: attitudes, well-being and quality of sex life. Contraception 64: 59–65.
Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C, Group HMCS, 2006 Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367: 1412–1420.
Behre HM, Nashan D, Hubert W, Nieschlag E, 1992 Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 74: 84–90.
Swerdloff RS, Bagatell CJ, Wang C, et al, 1998 Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab 83: 3527–3533.
Tomera K, Gleason D, Gittelman M, et al, 2001 The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 165: 1585–1589.
Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ, 2004 A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab 89: 5959–5965.
Struthers RS, Xie Q, Sullivan SK, et al, 2007 Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902. Endocrinology 148: 857–867.
Schlegel PN, Group HS, 2006 Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol 175: 1353–1358.
Meriggiola MC, Costantino A, Saad F, et al, 2005 Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab 90: 2005–2014.
Kamischke A, Venherm S, Plöger D, von Eckardstein S, Nieschlag E, 2001 Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86: 303–309.
Gui YL, He CH, Amory JK, et al, 2004 Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men. J Androl 25: 720–727.
Barfield A, Melo J, Coutinho E, et al, 1979 Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception 20: 121–127.
Turner L, Conway AJ, Jimenez M, et al, 2003 Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88: 4659–4667.
Gu YQ, Tong JS, Ma DZ, et al, 2004 Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in Chinese men. J Clin Endocrinol Metab 89: 2254–2262.
Meriggiola MC, Bremner WJ, Paulsen CA, et al, 1996 A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab 81: 3018–3023.
Meriggiola MC, Costantino A, Cerpolini S, et al, 2003 Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J Clin Endocrinol Metab 88: 5818–5826.
Ilani N, Roth MY, Amory JK, et al, 2012 A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab 97: 3476–3486.
Roth MY, Shih G, Ilani N, et al, 2014 Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception 90: 407–412.
Grimes DA, Lopez LM, Gallo MF, Halpern V, Nanda K, Schulz KF, 2012 Steroid hormones for contraception in men. Cochrane Database Syst Rev 3: CD004316.
Anderson RA, Kinniburgh D, Baird DT, 2002 Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab 87: 3640–3649.
Thompson IM, Goodman PJ, Tangen CM, et al, 2003 The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224.
Sundaram K, Kumar N, 2000 7alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy. Int J Androl 23 Suppl 2: 13–15.
von Eckardstein S, Noe G, Brache V, et al, 2003 A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 88: 5232–5239.
Diel P, Friedel A, Geyer H, et al, 2007 Characterisation of the pharmacological profile of desoxymethyltestosterone (Madol), a steroid misused for doping. Toxicol Lett 169: 64–71.
Brady BM, Anderson RA, 2002 Advances in male contraception. Expert Opin Investig Drugs 11: 333–344.
Amory JK, Anawalt BD, Bremner WJ, Matsumoto AM, 2001 Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development. J Androl 22: 1053–1060.
Amory JK, Page ST, Anawalt BD, Coviello AD, Matsumoto AM, Bremner WJ, 2007 Elevated end-of-treatment serum INSL3 is associated with failure to completely suppress spermatogenesis in men receiving male hormonal contraception. J Androl 28: 548–554.
Kornmann B, Nieschlag E, Zitzmann M, Gromoll J, Simoni M, von Eckardstein S, 2009 Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men. J Androl 30: 602–613.
Eckardstein SV, Schmidt A, Kamischke A, Simoni M, Gromoll J, Nieschlag E, 2002 CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol (Oxf) 57: 647–655.
Mruk DD, Lau AS, Sarkar O, Xia W, 2007 Rab4A GTPase catenin interactions are involved in cell junction dynamics in the testis. J Androl 28: 742–754.
Liu GZ, Lyle KC, Cao J, 1987 Experiences with gossypol as a male pill. Am J Obstet Gynecol 157: 1079–1081.
Qian SZ, 1987 Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception 36: 335–345.
Lopez LM, Grimes DA, Schulz KF, 2005 Nonhormonal drugs for contraception in men: a systematic review. Obstet Gynecol Surv 60: 746–752.
Mruk DD, Wong CH, Silvestrini B, Cheng CY, 2006 A male contraceptive targeting germ cell adhesion. Nat Med 12: 1323–1328.
Hild SA, Reel JR, Larner JM, Blye RP, 2001 Disruption of spermatogenesis and Sertoli cell structure and function by the indenopyridine CDB-4022 in rats. Biol Reprod 65: 1771–1779.
Hild SA, Reel JR, Dykstra MJ, Mann PC, Marshall GR, 2007 Acute adverse effects of the indenopyridine CDB-4022 on the ultrastructure of Sertoli cells, spermatocytes, and spermatids in rat testes: comparison to the known Sertoli cell toxicant Di-n-pentylphthalate (DPP). J Androl 28: 621–629.
Wolbach SB, Howe PR, 1925 Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med 42: 753–777.
Heller CG, Moore DJ, Paulsen CA, 1961 Suppression of spermatogenesis and chronic toxicity in men by a new series of bis(dichloroacetyl) diamines. Toxicol Appl Pharmacol 3: 1–11.
Amory JK, Muller CH, Shimshoni JA, et al, 2011 Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis. J Androl 32: 111–119.
Schulze GE, Clay RJ, Mezza LE, Bregman CL, Buroker RA, Frantz JD, 2001 BMS-189453, a novel retinoid receptor antagonist, is a potent testicular toxin. Toxicol Sci 59: 297–308.
Chung SS, Wang X, Roberts SS, Griffey SM, Reczek PR, Wolgemuth DJ, 2011 Oral administration of a retinoic Acid receptor antagonist reversibly inhibits spermatogenesis in mice. Endocrinology 152: 2492–2502.
Kandeel FR, Swerdloff RS, 1988 Role of temperature in regulation of spermatogenesis and the use of heating as a method for contraception. Fertil Steril 49: 1–23.
Voegeli M. 1956 Contraception through temporary male sterilization. Unpublished manuscript, Northampton, MA. Text available online at http://wwwpuzzlepiece.org/bcontrol/voegeli1956.txt.
Robinson D, Rock J, Menkin MF, 1968 Control of human spermatogenesis by induced changes of intrascrotal temperature. JAMA 204: 290–297.
Voegeli M. 1954 Data on the thermic method for temporary male sterilization. Unpublished manuscript, Northampton, MA. Text available at http://www.puzzle-piece.org/bcontrol/voegeli1954.txt.
Fahim MS, Fahim Z, Harman J, Thompson I, Montie J, Hall DG, 1977 Ultrasound as a new method of male contraception. Fertil Steril 28: 823–831.
VandeVoort CA, Tollner TL, 2012 The efficacy of ultrasound treatment as a reversible male contraceptive in the rhesus monkey. Reprod Biol Endocrinol 10: 81.
Tsuruta JK, Dayton PA, Gallippi CM, et al, 2012 Therapeutic ultrasound as a potential male contraceptive: power, frequency and temperature required to deplete rat testes of meiotic cells and epididymides of sperm determined using a commercially available system. Reprod Biol Endocrinol 10: 7.
Kempinas WD, Suarez JD, Roberts NL, et al, 1998 Rat epididymal sperm quantity, quality, and transit time after guanethidine-induced sympathectomy. Biol Reprod 59: 890–896.
Kedia K, Markland C, 1975 The effect of pharmacological agents on ejaculation. J Urol 114: 569–573.
Amobi N, Guillebaud J, Kaisary A, Lloyd-Davies RW, Turner E, Smith IC, 2003 Contractile actions of imidazoline alpha-adrenoceptor agonists and effects of noncompetitive alpha1-adrenoceptor antagonists in human vas deferens. Eur J Pharmacol 462: 169–177.
Homonnai ZT, Shilon M, Paz GF, 1984 Phenoxybenzamine—an effective male contraceptive pill. Contraception 29: 479–491.
Heath JW, Evans BK, Gannon BJ, Burnstock G, James VB, 1972 Degeneration of adrenergic neurons following guanethidine treatment: an ultrastructural study. Virchows Arch B Cell Pathol 11: 182–197.
Ventura S, Pennefather JN, 1991 Sympathetic co-transmission to the cauda epididymis of the rat: characterization of postjunctional adrenoceptors and purinoceptors. Br J Pharmacol 102: 540–544.
Ricker DD, Crone JK, Chamness SL, Klinefelter GR, Chang TS, 1997 Partial sympathetic denervation of the rat epididymis permits fertilization but inhibits embryo development. J Androl 18: 131–138.
Cooper TG, 1998 Interactions between epididymal secretions and spermatozoa. J Reprod Fertil Suppl 53: 119–136.
Hinton BT, Hernandez H, Howards SS, 1983 The male antifertility agents alpha chlorohydrin, 5-thio-D-glucose, and 6-chloro-6-deoxy-D-glucose interfere with sugar transport across the epithelium of the rat caput epididymidis. J Androl 4: 216–221.
Rodríguez CM, Labus JC, Hinton BT, 2002 Organic cation/carnitine transporter, OCTN2, is differentially expressed in the adult rat epididymis. Biol Reprod 67: 314–319.
Carr DW, Usselman MC, Acott TS, 1985 Effects of pH, lactate, and viscoelastic drag on sperm motility: a species comparison. Biol Reprod 33: 588–595.
Caflisch CR, DuBose TD, 1990 Direct evaluation of acidification by rat testis and epididymis: role of carbonic anhydrase. Am J Physiol 258: E143–150.
Jones AR, Cooper TG, 1999 Are-appraisal of the post-testicular action and toxicity of chlorinated antifertility compounds. Int J Androl 22: 130–138.
Singh AP, Rajender S, 2015 CatSper channel, sperm function and male fertility. Reprod Biomed Online 30: 28–38.
Carlson AE, Burnett LA, del Camino D, et al, 2009 Pharmacological targeting of native CatSper channels reveals a required role in maintenance of sperm hyperactivation. PLoS One 4: e6844.
Li H, Ding X, Guan H, Xiong C, 2009 Inhibition of human sperm function and mouse fertilization in vitro by an antibody against cation channel of sperm 1: the contraceptive potential of its transmembrane domains and pore region. Fertil Steril 92: 1141–1146.
Hall JC, Perez FM, Kochins JG, et al, 1996 Quantification and localization of N-acetyl-beta-D-hexosaminidase in the adult rat testis and epididymis. Biol Reprod 54: 914–929.
Tassi C, Angelini A, Beccari T, Capodicasa E, 2006 Fluorimetric determination of activity and isoenzyme composition of N-acetyl-beta-D-hexosaminidase in seminal plasma of fertile men and infertile patients with secretory azoospermia. Clin Chem Lab Med 44: 843–847.
Meinertz H, Linnet L, Fogh-Andersen P, Hjort T, 1990 Antisperm antibodies and fertility after vasovasostomy: a follow-up study of 216 men. Fertil Steril 54: 315–321.
Barfield JP, Nieschlag E, Cooper TG, 2006 Fertility control in wildlife: humans as a model. Contraception 73: 6–22.
Nieschlag E, Henke A, 2005 Hopes for male contraception. Lancet 365: 554–556.
O’rand MG, Widgren EE, Sivashanmugam P, et al, 2004 Reversible immunocontraception in male monkeys immunized with eppin. Science 306: 1189–1190.
Qin Y, Han Y, Xiong CL, Li HG, Hu L, Zhang L, 2014 Urokinase-type plasminogen activator: a new target for male contraception? Asian J Androl 16: 623–630.
Naz RK, Gupta SK, Gupta JC, Vyas HK, Talwar AG, 2005 Recent advances in contraceptive vaccine development: a mini-review. Hum Reprod 20: 3271–3283.
Xu C, Li YC, Yang H, et al, 2014 The preparation and application of N-terminal 57 amino acid protein of the follicle-stimulating hormone receptor as a candidate male contraceptive vaccine. Asian J Androl 16: 623–630.
Guha SK, Singh G, Anand S, Ansari S, Kumar S, Koul V, 1993 Phase I clinical trial of an injectable contraceptive for the male. Contraception 48: 367–375.
Guha SK, Singh G, Ansari S, et al, 1997 Phase II clinical trial of a vas deferens injectable contraceptive for the male. Contraception 56: 245–250.
Lohiya NK, Alam I, Hussain M, Khan SR, Ansari AS, 2014 RISUG: An intravasal injectable male contraceptive. Indian J Med Res 140 Suppl: S63–72.
Chaki SP, Das HC, Misro MM, 2003 A short-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG. Contraception 67: 73–78.
Zhao SC, 1990 Vas deferens occlusion by percutaneous injection of polyurethane elastomer plugs: clinical experience and reversibility. Contraception 41: 453–459.
Lohiya NK, Manivannan B, Mishra PK, Pathak N, 2001 Vas deferens, a site of male contraception: an overview. Asian J Androl 3: 87–95.
Zhao SC, Lian YH, Yu RC, Zhang SP, 1992 Recovery of fertility after removal of polyurethane plugs from the human vas deferens occluded for up to 5 years. Int J Androl 15: 465–467.
Amory JK, Muller CH, Page ST, et al, 2007 Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod 22: 702–707.
Matzuk MM, McKeown MR, Filippakopoulos P, et al, 2012 Small-molecule inhibition of BRDT for male contraception. Cell 150: 673–684.
Rahman MS, Lee JS, Kwon WS, Pang MG, 2013 Sperm proteomics: road to male fertility and contraception. Int J Endocrinol 2013: 360986.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kanakis, G.A., Goulis, D.D. Male contraception: a clinically-oriented review. Hormones 14, 598–614 (2015). https://doi.org/10.14310/horm.2002.1623
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1623